EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate By Ogkologos - February 20, 2026 46 0 Facebook Twitter Google+ Pinterest WhatsApp New combination concerns a combination with ADT for the treatment of adult patients with mHSPC and BRCA1/2 mutations Source RELATED ARTICLESMORE FROM AUTHOR New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology MOST POPULAR Robin Williams Required Film Companies He Worked With To Hire Homeless... November 25, 2021 Using a Mind-Body Connection to Help You Cope During Cancer: An... January 11, 2024 Doxorubicin and Trabectedin Combination Improves Survival Among Patients with Metastatic or... September 13, 2024 Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer... April 6, 2022 Load more HOT NEWS ESMO awards its first fellowship to support digital and computational pathology Temporary Interruption of Adjuvant Endocrine Treatment to Attempt Pregnancy Does Not... Adjuvant Abemaciclib Combined with Endocrine Therapy Improves IDFS in HR-Positive, HER2−Negative,... Durable Activity of Repotrectinib in Patients with ROS1 Fusion–Positive NSCLC Regardless...
